


## Magnesium Sulfate for Neuroprotection



## REFERENCES

1. Magnesium sulfate before anticipated preterm birth for neuroprotection. Committee Opinion No. 455. American College of Obstetricians and Gynecologists. *Obstet Gynecol.* 2010;115:669–671.
2. Rouse D, Hirtz D, Thom E, Varner M, Spong C, Mercer B, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. *N Engl J Med.* 2008;359:895–905.
3. Raju T, Mercer B, Burchfield D, Joseph G. Periviable birth: Executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Academy of Pediatrics, and American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2014;123(5):1083-1096.
4. Periviable birth. Obstetric care Consensus No.4. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2016;127:e157-69.
5. Doyle L, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. *Cochrane Database of Systematic Reviews* 2009, Issue 1. Art. No.: CD004661. DOI: 10.1002/14651858.CD004661.pub3.
6. Crowther C, Hiller J, Doyle L, Haslam R. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. Australian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. *JAMA.* 2003;290:2669–2676.
7. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Leveque C, Hellot M, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. PREMAG trial group. *BJOG.* 2007;114:310–318.
8. Marret S, Marpeau L, Follet-Bouhamed C, Cambonie G, Astruc D, Delaporte B, et al. Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective PREMAG trial. le groupe PREMAG [French]. *Gynecol Obstet Fertil.* 2008;36:278–288.
9. Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and meta-analysis. *Am J Obstet Gynecol.* 2009;200:595–609.
10. Doyle L, Crowther C, Middleton P, Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants. *Obstet Gynecol.* 2009;113(6):1327-1333.
11. Palatnik A, Rouse D, Stamilio D, McPherson J, Grobman W. Association between cerebral palsy or death and umbilical cord blood magnesium concentration. *Am J Perinatol.* 2015 Nov;32(13):1263-1267.
12. McPherson, J, Rouse D, Grobman W, Palatnik A, Stamilio D. Association of duration of neuroprotective magnesium sulfate with neonatal and maternal outcomes. *Obstet Gynecol.* 2014 Oct;124(4):749-755.
13. Turitz AL, Too GT, Gyamati-Bannerman, C. Proximity of magnesium exposure to delivery and neonatal outcomes. *Am J Obstet Gynecol.* 2016 Oct;215:508.

*These algorithms are designed to assist the primary care provider in the clinical management of a variety of problems that occur during pregnancy. They should not be interpreted as a standard of care, but instead represent guidelines for management. Variation in practices should take into account such factors as characteristics of the individual patient, health resources, and regional experience with diagnostic and therapeutic modalities. The algorithms remain the intellectual property of the University of North Carolina at Chapel Hill School of Medicine. They cannot be reproduced in whole or in part without the expressed written permission of the school. [www.mombaby.org](http://www.mombaby.org)*